News

Fierce Biotech16h
GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win
GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...
Endpoints News14h
GSK, Spero re­port Phase 3 win for UTI an­tibi­ot­ic; Sper­o's stock soars
GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, ...
GSK, Spero stop UTI drug trial after early success
Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...
Spero surges as GSK-partnered UTI candidate succeeds in late-stage trial
Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...
Stocktwits on MSN15h
GSK, Spero Therapeutics Stop Antibiotic Trial For Complicated Urinary Tract Infections Early After Positive Results, Retail’s Thrilled
British pharmaceutical company GSK PLC (GSK) and its Massachusetts-based partner Spero Therapeutics (SPRO) said on Wednesday ...
Zacks Investment Research on MSN13h
ATGE or UTI: Which Is the Better Value Stock Right Now?
Investors interested in Schools stocks are likely familiar with Adtalem Global Education (ATGE) and Universal Technical Institute (UTI). But which of these two stocks presents investors with the ...